Cormedix Inc (NYSEMKT:CRMD) Sentiment Report

June 25, 2018 - By Rene Maslow


Sentiment for Cormedix Inc (NYSEMKT:CRMD)

Cormedix Inc (NYSEMKT:CRMD) institutional sentiment decreased to 0.82 in 2018 Q1. Its down -0.43, from 1.25 in 2017Q4. The ratio fall, as 9 investment professionals increased and started new stock positions, while 11 sold and reduced holdings in Cormedix Inc. The investment professionals in our partner’s database reported: 3.59 million shares, down from 3.71 million shares in 2017Q4. Also, the number of investment professionals holding Cormedix Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 5 Reduced: 6 Increased: 5 New Position: 4.

CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and other markets. The company has market cap of $19.35 million. The Company’s primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. It currently has negative earnings. The firm was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007.

The stock increased 1.72% or $0.004 during the last trading session, reaching $0.2362. About 1.09 million shares traded. CorMedix, Inc. (NYSEMKT:CRMD) has declined 55.43% since June 25, 2017 and is downtrending. It has underperformed by 68.00% the S&P500.

Bank Of America Corp De holds 0% of its portfolio in CorMedix, Inc. for 2,000 shares. Bank Of New York Mellon Corp owns 45,320 shares or 0% of their US portfolio. Moreover, Barclays Plc has 0% invested in the company for 54 shares. The New York-based Blackrock Inc. has invested 0% in the stock. Bnp Paribas Arbitrage Sa, a New York-based fund reported 23 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.